MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.
